Eli Lil­ly ax­es 163 Der­mi­ra staffers, shut­ters Men­lo Park site as it clos­es in around Dupix­ent ri­val le­brik­izum­ab

Eli Lil­ly made it clear when it shelled out $1.1 bil­lion for Der­mi­ra that le­brik­izum­ab is re­al­ly what it want­ed to buy. One year in, the phar­ma gi­ant is com­plet­ing its cleav­age of the rest.

Days af­ter un­veil­ing the sale of Qbexza — Der­mi­ra’s on­ly ap­proved prod­uct, a piece of cloth to block ex­ces­sive sweat­ing — Lil­ly re­vealed plans to close down the biotech’s Men­lo Park fa­cil­i­ty, putting 163 jobs on the chop­ping block. The San Fran­cis­co Busi­ness Times first re­port­ed on the WARN no­tice filed in ear­ly April.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.